E71.510
Zellweger syndrome
Clinical Classification Guidelines
Medical Intelligence & Overview
Zellweger syndrome is a rare inherited disorder that affects the functioning of many organs and tissues in the body. It is classified as a peroxisome biogenesis disorder, leading to the improper formation and function of peroxisomes—cell structures responsible for breaking down fatty acids and other toxic substances. The condition is typically diagnosed in infancy and is characterized by multiple developmental and physical abnormalities. Due to its complexity and severity, Zellweger syndrome often results in significant health challenges and a shortened lifespan.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting the PEX genes, which are vital for peroxisome formation Autosomal recessive inheritance pattern, meaning an affected child inherits two copies of the mutated gene, one from each parent No known environmental or lifestyle factors have been linked to the development of Zellweger syndrome
Key Symptoms: Distinct facial features, such as high forehead, broad nasal bridge, and a pointed chin Hypotonia (poor muscle tone) leading to weak and floppy muscles Seizures and neurological impairments Liver dysfunction, including hepatomegaly (enlarged liver) Failure to thrive and inability to gain weight Developmental delays or absence of developmental milestones Vision and hearing problems Elevated levels of very long-chain fatty acids in the blood Characteristic abnormalities in the brain's structure observed via imaging studies
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Zellweger syndrome involves a combination of clinical assessment, laboratory tests, and imaging studies. Key diagnostic procedures include: - Blood tests revealing elevated very long-chain fatty acids - Genetic testing to identify mutations in PEX genes - Ultrasound and MRI scans to observe structural abnormalities in the brain and other organs - Examination of tissues obtained through biopsy, if necessary, demonstrating defective peroxisome formation Accurate diagnosis often requires an experienced multidisciplinary team, given the condition's complexity
Treatment Protocols: Currently, there is no cure for Zellweger syndrome. Management aims to support the affected individual through symptomatic treatment and supportive care, which may involve: - Nutritional support to promote growth and prevent deficiencies - Physical and occupational therapy to enhance motor skills - Seizure management with appropriate medications - Regular monitoring of liver function and other organ systems - Addressing vision and hearing impairments - Providing genetic counseling for families to understand inheritance patterns and recurrence risks Research and clinical trials are ongoing to explore potential therapies and management strategies that may improve quality of life for individuals with this condition.
Clinical Advice & FAQs
Billing Guidance
Is E71.510 a billable ICD-10 code?
Yes, E71.510 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E71.510?
Clinical documentation must specify the nature of Zellweger syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference